Next generation of antibody therapy for cancer

Chinese Journal of Cancer

Volumn 30, Issue 5, 2011, Pages 293-302

  Zhu, Zhenping ^a   Yan, Li ^b,c  

^a Kadmon Pharmaceuticals   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

^c PEKING UNIVERSITY CANCER HOSPITAL AND INSTITUTE   (China)

Author keywords

Antibodies; Antibody engineering; Cancer; Cancer therapeutics

Indexed keywords

ALEMTUZUMAB; ANTHRACYCLINE; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CAPECITABINE; CARBOPLATIN; CD20 ANTIGEN; CETUXIMAB; CISPLATIN; DENOSUMAB; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FLUDARABINE; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; IBRITUMOMAB TIUXETAN; IDEC C 2B8; IRINOTECAN; MONOCLONAL ANTIBODY; NAVELBINE; OFATUMUMAB; OXALIPLATIN; PACLITAXEL; PANITUMUMAB; PERTUZUMAB; PLACEBO; RITUXIMAB; TOSITUMOMAB I 131; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN; ZOLEDRONIC ACID;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIBODY DRUG CONJUGATE TECHNOLOGY; ANTIBODY SPECIFICITY; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; ARTERIAL THROMBOEMBOLISM; B CELL LEUKEMIA; B CELL LYMPHOMA; BIOTECHNOLOGY; BONE DENSITY; BONE METASTASIS; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; COLORECTAL CANCER; DRUG APPROVAL; DRUG DOSE COMPARISON; DRUG HALF LIFE; DRUG INDICATION; DRUG MEGADOSE; DRUG RECEPTOR BINDING; DRUG RESPONSE; DRUG TARGETING; FOLLICULAR LYMPHOMA; GENE OVEREXPRESSION; HEAD AND NECK CANCER; HEART DISEASE; HUMAN; HYPERTENSION; LOW DRUG DOSE; LUNG NON SMALL CELL CANCER; METASTASIS; MONOTHERAPY; NONHODGKIN LYMPHOMA; NONHUMAN; ONCOGENE K RAS; ONCOGENE NEU; OVARY CANCER; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; PROTEIN ENGINEERING; PROTEIN GLYCOSYLATION; PROTEINURIA; RECEPTOR AFFINITY; REVIEW; SQUAMOUS CELL CARCINOMA; STRUCTURE ACTIVITY RELATION; SURVIVAL TIME; THROMBOEMBOLISM; VERTEBRA FRACTURE;

EID: 79958181090     PISSN: 1000467X     EISSN: 1944446X     Source Type: Journal    
DOI: 10.5732/cjc.011.10123     Document Type: Review

References (77)

1. Kohler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity [J]. Nature, 1975,256(5517):495-497.
2. Morrison SL, Johnson MJ, Herzenberg LA, et al. Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains [J]. Proc Natl Acad Sci U S A, 1984,81(21):6851-6855.
3. Jones PT, Dear PH, Foote J, et al. Replacing the complementarity-determining regions in a human antibody with those from a mouse [J]. Nature, 1986,321(6069):522-525.
4. Queen C, Schneider WP, Selick HE, et al. A humanized antibody that binds to the interleukin 2 receptor [J]. Proc Natl Acad Sci U S A, 1989,86(24):10029-10033.
5. Clackson T, Hoogenboom HR, Griffiths AD, et al. Making antibody fragments using phage display libraries [J]. Nature, 1991,352(6336):624-628.
6. Taylor LD, Carmack CE, Schramm SR, et al. A transgenic mouse that expresses a diversity of human sequence heavy and light chain immunoglobulins [J]. Nucleic Acids Res, 1992,20(23):6287-6295.
7. Lonberg N, Taylor LD, Harding FA, et al. Antigen-specific human antibodies from mice comprising four distinct genetic modifications [J]. Nature, 1994,368 (6474):856-859.
8. Green LL, Hardy MC, Maynard-Currie CE, et al. Antigen specific human monoclonal antibodies from mice engineered with human Ig heavy and light chain YACs [J]. Nat Genet,1994,7(1):13-21.
9. Yan L, Zhu Z. Development of antibody-based therapeutics for oncology indications [J]. Drug Dev Res, 2006,67(9):699-728.
10. Yan L, Ehrlich PJ, Gibson R, et al. How can we improve antibody-based cancer therapy? [J]. MAbs, 2009,1(1):67-70.
11. Shan D, Ledbetter JA, Press OW. Signaling events involved in anti-C D20-induced apoptosis of malignant human B cells [J]. Cancer Immunol Immunother, 2000,48(12):673-683
12. Shan D, Gopal AK, Press OW. Synergistic effects of the fenretinide (4-H PR) and anti-C D20 monoclonal antibodies on apoptosis induction of malignant human B cells [J]. Clin Cancer Res, 2001,7(8):2490-2495.
13. Shan D, Ledbetter JA, Press OW. Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies [J]. Blood, 1998,91(5):1644-1652.
14. Reff ME, Carner K, Chambers KS, et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20 [J]. Blood, 1994,83(2):435-445.
15. McLaughlin P, Grillo-Lopez AJ, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program [J]. J Clin Oncol, 1998,16(8):2825-2833.
16. Krasner C, Joyce RM. Zevalin: 90yttrium labeled anti-C D20 (ibritumomab tiuxetan), a new treatment for non-H odgkin's lymphoma [J]. Curr Pharm Biotechnol, 2001,2(4):341-349.
17. Cheson B. Bexxar (Corixa/GlaxoSmithKline) [J]. Curr Opin Investig Drugs, 2002,3(1):165-170.
18. Cheson BD. Ofatumumab, a novel anti-CD20 monoclonal antibody for the treatment of B-cell malignancies [J]. J Clin Oncol, 2010,28(21):3525-3530.
19. Lemery SJ, Zhang J, Rothmann MD, et al. U.S. Food and Drug Administration approval: ofatumumab for the treatment of patients with chronic lymphocytic leukemia refractory to fludarabine and alemtuzumab [J]. Clin Cancer Res, 2010,16 (17):4331-4338.
20. Wierda WG, Kipps TJ, Mayer J, et al. Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia [J]. J Clin Oncol, 2010,28 (10):1749-1755.
21. Slamon DJ, Godolphin W, Jones LA, et al. Studies of the HER-2/neu proto-on cogene in human breast and ovarian cancer [J]. Science, 1989,244 (4905):707-712.
22. Cobleigh MA, Vogel CL, Tripathy D, et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-ov erexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease [J]. J Clin Oncol, 1999,17(9):2639-2648.
23. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2 [J]. N Engl J Med, 2001,344(11):783-792.
24. Baselga J, Gelmon KA, Verma S, et al. Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy [J]. J Clin Oncol, 2010,28(7):1138-1144.
25. Baselga J, Swain SM. CLEOPATRA: a phase III evaluation of pertuzumab and trastuzumab for HER2-positive metastatic breast cancer [J]. Clin Breast Cancer, 2010,10(6):489-491.
26. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer [J]. N Engl J Med, 2004,350(23):2335-2342.
27. Giantonio BJ, Catalano PJ, Meropol NJ, et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200 [J]. J Clin Oncol, 2007,25(12):1539-1544.
28. Sandler AB, Gray R, Brahmer J, et al. Randomized phase II/III Trial of paclitaxel (P) plus carboplatin (C) with or without bevacizumab (NSC # 704865) in patients with advanced non-squamous non-small cell lung cancer (NSCLC): An Eastern Cooperative Oncology Group (ECOG) Trial - E4599 [A]. J Clin Oncol, 2005 ASCO Annual Meeting Proceedings, 2005,23 (16S): 4.
29. Reck M, von Pawel J, Zatloukal P, et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil [J]. J Clin Oncol, 2009,27(8):1227-1234.
30. Reck M, von Pawel J, Zatloukal P, et al. Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL) [J]. Ann Oncol, 2010,21(9):1804-1809.
31. Miller KD, Chap LI, Holmes FA, et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer [J]. J Clin Oncol, 2005,23(4):792-799.
32. Miller K, Wang M, Gralow J, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer [J]. N Engl J Med, 2007,357(26):2666-2676.
33. Robert NJ, Dieras V, Glaspy J, et al. RIBBON-1: randomized, double-blind, placebo-co ntrolled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer [J]. J Clin Oncol, 2011,29(10): 1252-1260.
34. Nicholson RI, Gee JM, Harper ME. EGFR and cancer prognosis [J]. Eur J Cancer, 2001,37 Suppl 4:S9-S15.
35. Amado RG, Wolf M, Peeters M, et al. Wild-ty pe KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer [J]. J Clin Oncol, 2008,26(10): 1626-1634.
36. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer [J]. N Engl J Med, 2004,351 (4):337-345.
37. Jonker DJ, O'Callaghan CJ, Karapetis CS, et al. Cetuximab for the treatment of colorectal cancer [J]. N Engl J Med, 2007,357(20):2040-2048.
38. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck [J]. N Engl J Med, 2006,354(6):567-578.
39. Vermorken JB, Mesia R, Rivera F, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer [J]. N Engl J Med, 2008,359(11):1116-1127.
40. van Cutsem E, Peeters M, Siena S, et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer [J]. J Clin Oncol, 2007,25(13): 1658-1664.
41. Cross J. DxS Ltd [J]. Pharmacogenomics, 2008,9(4):463-467.
42. Smith MR, Egerdie B, Hernandez Toriz N, et al. Denosumab in men receiving androgen-deprivation therapy for prostate cancer [J]. N Engl J Med, 2009,361 (8):745-755.
43. Stopeck AT, Lipton A, Body JJ, et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study [J]. J Clin Oncol, 2010,28(35):5132-5139.
44. Stasi R, Evangelista ML, Buccisano F, et al. Gemtuzumab ozogamicin in the treatment of acute myeloid leukemia [J]. Cancer Treat Rev, 2008,34(1):49-60.
45. Silverman DH, passand ES, Torabi F, et al. Radiolabeled antibody therapy in non-Hodgkins lymphoma: radiation protection, isotope comparisons and quality of life issues [J]. Cancer Treat Rev, 2004,30(2):165-172.
46. Lewis Phillips GD, Li G, Dugger DL, et al. Targeting HER2-positive breast cancer with trastuzumab-D M1, an antibody-cytotoxic drug conjugate [J]. Cancer Res, 2008,68, 9280-9290.
47. Burris HA 3rd, Rugo HS, Vukelja SJ, et al. Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy [J]. J Clin Oncol, 2010,29(4):398-405.
48. Ansell SM. Brentuximab vedotin: delivering an antimitotic drug to activated lymphoma cells [J]. Expert Opin Investig Drugs, 2011,20(1):99-105.
49. Carter PJ, Senter PD. Antibody-drug conjugates for cancer therapy [J]. Cancer J, 2008,14(3):154-169.
50. Marvin JS, Zhu Z. Bi specific antibodies for dual-modality cancer therapy: killing two signaling cascades with one stone [J]. Curr Opin Drug Discov Devel, 2006,9(2):184-193.
51. Lu D, Jimenez X, Zhang H, et al. Complete inhibition of vascular endothelial growth factor (VEGF) activities with a bi functional diabody directed against both VEGF kinase receptors, fms-lik e tyrosine kinase receptor and kinase insert domain-containing receptor [J]. Cancer Res, 2001,61 (19): 7002-7008.
52. Lu D, Zhang H, Ludwig D, et al. Simultaneous blockade of both the epidermal growth factor receptor and the insulin-like growth factor receptor signaling pathways in cancer cells with a fully human recombinant bi specific antibody [J]. J Biol Chem, 2004,279(4):2856-2865.
53. Lu D, Zhang H, Koo H, et al. A fully human recombinant IgG-like bi specific antibody to both the epidermal growth factor receptor and the insulin-like growth factor receptor for enhanced antitumor activity [J]. J Biol Chem, 2005,280 (20): 19665-19672.
54. Robinson MK, Hodge KM, Horak E, et al. Targeting ErbB2 and ErbB3 with a bi specific single-chain Fv enhances targeting selectivity and induces a therapeutic effect in vitro [J]. Br J Cancer, 2008,99(9):1415-1425.
55. Shen J, Vil MD, Prewett M, et al. Development of a fully human anti-PDGFRbeta antibody that suppresses growth of human tumor xenografts and enhances antitumor activity of an anti-VEGFR2 antibody [J]. Neoplasia, 2009,11(6):594-604.
56. Lu D, Kotanides H, Jimenez X, et al. Acquired antagonistic activity of a bi specific diabody directed against two different epitopes on vascular endothelial growth factor receptor 2 [J]. J Immunol Methods, 1999,230(1-2):159-171.
57. Cartron G, Dacheux L, Salles G, et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor Fcgamma RIIIa gene [J]. Blood, 2002,99 (3):754-758.
58. Musolino A, Naldi N, Bortesi B, et al. Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/ neu-positive metastatic breast cancer [J]. J Clin Oncol, 2008,26(11):1789-1796.
59. Lejeune J, Thibault G, Ternant D, et al. Evidence for linkage disequilibrium between Fcgamma RIIIa-V158F and Fcgamma RIIa-H131R polymorphisms in white patients, and for an Fcgamma RIIIa-restricted influence on the response to therapeutic antibodies [J]. J Clin Oncol, 2008,26 (33):5489-5491.
60. Shields RL, Namenuk AK, Hong K, et al. High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R [J]. J Biol Chem, 2001,276, 6591-6604.
61. Lazar GA, Dang W, Karki S, et al. Engineered antibody Fc variants with enhanced effectors function [J]. Proc Natl Acad Sci U S A, 2006,103(11):4005-4010.
62. Desjarlais JR, Lazar GA, Zhukovsky EA, et al. Optimizing engagement of the immune system by anti-tumor antibodies: an engineer's perspective [J]. Drug Discov Today, 2007,12 (21-22)898-910
63. Allan B. Variant Fc regions. ed. Applied Molecular Evolution [P]. PCT/US2006/025276. 2010.
64. Hansen G, et al. Diversa/Medarex. Altered antibody Fc regions and uses thereof [P]. PCT/US2006/011048. 2010.
65. Siberil S, Dutertre CA, Boix C, et al. Molecular aspects of human Fc gamma R interactions with IgG: functional and therapeutic consequences [J]. Immunol Lett, 2006,106(2):111-118.
66. Horton HM, Bernett MJ, Pong E, et al. Potent in vitro and in vivo activity of an Fc-engineered anti-CD19 monoclonal antibody against lymphoma and leukemia [J]. Cancer Res, 2008,68(19):8049-8057.
67. Natsume A, In M, Takamura H, et al. Engineered antibodies of IgG1/IgG3 mixed isotype with enhanced cytotoxic activities [J]. Cancer Res, 2008,68(10):3863-3872.
68. Yamane-Ohnuki N, Kinoshita S, Inoue-Urakubo M, et al. Establishment of FUT8 knockout Chinese hamster ovary cells: an ideal host cell line for producing completely defucosylated antibodies with enhanced antibody-dependent cellular cytotoxicity [J]. Biotechnol Bioeng, 2004,87(5):614-622.
69. Umana P, Jean-Mairet J, Moudry R, et al. Engineered glycoforms of an antineuroblastoma IgG1 with optimized antibody-dependent cellular cytotoxic activity [J]. Nat Biotech, 1999,17(2):176-180.
70. Dall'Acqua WF, Kiener PA, Wu H. Properties of human IgG1s engineered for enhanced binding to the neonatal Fc receptor (FcRn) [J]. J Biol Chem, 2006,281 (33):23514-23524.
71. Oganesyan V, Damschroder MM, Woods RM, et al. Structural characterization of a human Fc fragment engineered for extended serum half-life [J]. Mol Immunol, 2009,46 (8-9): 1750-1755.
72. Yeung YA, Wu X, Reyes AE 2nd, et al. A therapeutic anti VEGF antibody with increased potency independent of pharmacokinetic half-life [J]. Cancer Res, 2010,70 (8):3269-3277.
73. Zalevsky J, Chamberlain AK, Horton HM, et al. Enhanced antibody half-life improves in vivo activity [J]. Nat Biotechnol, 2010,28(2):157-159.
74. Hinton PR, Xiong JM, Johlfs MG, et al. An engineered human IgG1 antibody with longer serum half-life [J]. J Immunol, 2006,176(1):346-356.
75. Hinton PR, Johlfs MG, Xiong JM, et al. Engineered human IgG antibodies with longer serum half-lives in primates [J]. J Biol Chem, 2004,279(8):6213-6216.
76. Datta-Mannan A, Witcher DR, Tang Y, et al. Monoclonal antibody clearance. Impact of modulating the interaction of IgG with the neonatal Fc receptor [J]. J Biol Chem, 2007,282(3): 1709-1717.
77. World's top-selling drugs in 2014 vs 2010 [R]. 2010. Reuters News. 4-13-2010.